Effect of gefitinib on the survival of patients with recurrence of lung adenocarcinoma after surgery: A retrospective case-matching cohort study

Surgical Oncology

Volumn 19, Issue 4, 2010, Pages

  Katayama, Tatsuya ^a,c   Matsuo, Keitaro ^a   Kosaka, Takayuki ^b   Sueda, Taijiro ^c   Yatabe, Yasushi ^a   Mitsudomi, Tetsuya ^a  

^a AICHI CANCER CENTER HOSPITAL   (Japan)

^b GUNMA UNIVERSITY   (Japan)

^c HIROSHIMA UNIVERSITY   (Japan)

Author keywords

EGFR mutation; Gefitinib; Lung cancer; Survival benefit; TKI

Indexed keywords

GEFITINIB;

ADULT; ARTICLE; CANCER RECURRENCE; CANCER SURVIVAL; CONTROLLED STUDY; DRUG EFFECT; FEMALE; GENE DELETION; GENE MUTATION; GENETIC ANALYSIS; HUMAN; LUNG ADENOCARCINOMA; LUNG SURGERY; MAJOR CLINICAL STUDY; MALE; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROGNOSIS;

ADENOCARCINOMA; AGED; ANTINEOPLASTIC AGENTS; CASE-CONTROL STUDIES; EXONS; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; POINT MUTATION; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RETROSPECTIVE STUDIES; SEQUENCE DELETION; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 77957812460     PISSN: 09607404     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.suronc.2010.07.002     Document Type: Article

References (29)

1. J.H. Schiller, D. Harrington, C.P. Belani, C. Langer, A. Sandler, and J. Krook Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer N Engl J Med 346 2002 92 98 (Pubitemid 34438899)
2. Y. Ohe, Y. Ohashi, K. Kubota, T. Tamura, K. Nakagawa, and S. Negoro Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: four-arm cooperative study in Japan Ann Oncol 18 2007 317 323
3. T. Mitsudomi, T. Kosaka, and Y. Yatabe Biological and clinical implications of EGFR mutations in lung cancer Int J Clin Oncol 11 2006 190 198
4. S. Toyooka, T. Takano, T. Kosaka, K. Hotta, K. Matsuo, and S. Ichihara Epidermal growth factor receptor mutation, but not sex and smoking, is independently associated with favorable prognosis of gefitinib-treated patients with lung adenocarcinoma Cancer Sci 99 2008 303 308
5. M. Fukuoka, S. Yano, G. Giaccone, T. Tamura, K. Nakagawa, and J.Y. Douillard Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected] J Clin Oncol 21 2003 2237 2246
6. M.G. Kris, R.B. Natale, R.S. Herbst, T.J. Lynch Jr., D. Prager, and C.P. Belani Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small-cell lung cancer: a randomized trial Jama 290 2003 2149 2158
7. T.J. Lynch, D.W. Bell, R. Sordella, S. Gurubhagavatula, R.A. Okimoto, and B.W. Brannigan Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib N Engl J Med 350 2004 2129 2139
8. J.G. Paez, P.A. Janne, J.C. Lee, S. Tracy, H. Greulich, and S. Gabriel EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy Science 304 2004 1497 1500
9. L.V. Sequist, R.G. Martins, D. Spigel, S.M. Grunberg, A. Spira, and P.A. Jänne First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations J Clin Oncol 26 2008 2442 2449
10. K. Yoshida, Y. Yatabe, J.Y. Park, J. Shimizu, Y. Horio, and K. Matsuo Prospective validation for prediction of gefitinib sensitivity by epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer J Thorac Oncol 2 2007 22 28 (Pubitemid 47163924)
11. A. Sutani, Y. Nagai, K. Udagawa, Y. Uchida, N. Koyama, and Y. Murayama Gefitinib for non-small-cell lung cancer patients with epidermal growth factor receptor gene mutations screened by peptide nucleic acid-locked nucleic acid PCR clamp Br J Cancer 95 2006 1483 1489
12. K. Tamura, I. Okamoto, T. Kashii, S. Negoro, T. Hirashima, and S. Kudoh Multicentre prospective phase II trial of gefitinib for advanced non-small-cell lung cancer with epidermal growth factor receptor mutations: results of the West Japan Thoracic Oncology Group trial (WJTOG0403) Br J Cancer 98 2008 907 914
13. A. Inoue, T. Suzuki, T. Fukuhara, M. Maemondo, Y. Kimura, and N. Morikawa Prospective phase II study of gefitinib for chemotherapy-naive patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutations J Clin Oncol 24 2006 3340 3346
14. S. Morita, I. Okamoto, K. Kobayashi, K. Yamazaki, H. Asahina, and A. Inoue Combined survival analysis of prospective clinical trials of gefitinib for non-small-cell lung cancer with EGFR mutations Clin Cancer Res 15 2009 4493 4498
15. T. Mok, Y.L. Wu, S. Thongprasert, C.H. Yang, D.T. Chu, and N. Saijo Phase III, randomized, open-label, first-line study of gefitinib (G) vs carboplatin/paclitaxel (C/P) in clinically selected patients (pts) with advanced non-small-cell lung cancer (NSCLC) (IPASS) Ann Oncol 19 Suppl. 8 2008 LB
16. N. Thatcher, A. Chang, P. Parikh, J. Rodrigues Pereira, and T. Ciuleanu Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa survival evaluation in lung cancer) Lancet 366 2005 1527 1537
17. R.S. Herbst, G. Giaccone, J.H. Schiller, R.B. Natale, V. Miller, and C. Manegold Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT 2 J Clin Oncol 22 2004 785 794 (Pubitemid 41103589)
18. G. Giaccone, R.S. Herbst, C. Manegold, G. Scagliotti, R. Rosell, and V. Miller Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT 1 J Clin Oncol 22 2004 777 784 (Pubitemid 41103588)
19. K. Kelly, K. Chansky, L.E. Gaspar, K.S. Albain, J. Jett, and Y.C. Ung Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer: SWOG S0023 J Clin Oncol 26 2008 2450 2456
20. R. Maruyama, Y. Nishiwaki, T. Tamura, N. Yamamoto, M. Tsuboi, and K. Nakagawa Phase III study, V15-32, of gefitinib versus docetaxel in previously treated Japanese patients with non-small-cell lung cancer J Clin Oncol 26 2008 4244 4252
21. T. Mitsudomi, and Y. Yatabe Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer Cancer Sci 98 2007 1817 1824
22. Y. Yatabe, T. Kosaka, T. Takahashi, and T. Mitsudomi EGFR mutation is specific for terminal respiratory unit type adenocarcinoma Am J Surg Pathol 29 2005 633 639
23. T. Kosaka, Y. Yatabe, H. Endoh, H. Kuwano, T. Takahashi, and T. Mitsudomi Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications Cancer Res 64 2004 8919 8923
24. T. Mitsudomi, T. Kosaka, H. Endoh, Y. Horio, T. Hida, and S. Mori Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence J Clin Oncol 23 2005 2513 2520
25. T. Kosaka, Y. Yatabe, R. Onozato, H. Kuwano, and T. Mitsudomi Prognostic implication of EGFR, KRAS, and TP53 gene mutations in a large cohort of Japanese patients with surgically treated lung adenocarcinoma J Thorac Oncol 4 2009 22 29
26. J.L. Marks, S. Broderick, Q. Zhou, D. Chitale, A.R. Li, and M.F. Zakowski Prognostic and therapeutic implications of EGFR and KRAS mutations in resected lung adenocarcinoma J Thorac Oncol 3 2008 111 116
27. T. Takano, T. Fukui, Y. Ohe, K. Tsuta, S. Yamamoto, and H. Nokihara EGFR mutations predict survival benefit from gefitinib in patients with advanced lung adenocarcinoma: a historical comparison of patients treated before and after approval in Japan J Clin Oncol 26 2008 5589 5595
28. A. Inoue, K. Kobayashi, K. Usui, M. Maemondo, S. Okinaga, and I. Mikami First-line gefitinib for patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutations without indication for chemotherapy J Clin Oncol 27 2009 1394 1400
29. I. Sekine, H. Nokihara, N. Yamamoto, H. Kunitoh, Y. Ohe, and T. Tamura Comparative chemotherapeutic efficacy in non-small-cell lung cancer patients with postoperative recurrence and stage IV disease J Thorac Oncol 4 2009 518 521